Praxis Precision Medicines to Participate in Upcoming Fireside Chat
Praxis Precision Medicines (NASDAQ:PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, has announced its participation in an upcoming virtual fireside chat. CEO Marcio Souza will engage in a discussion with Piper Sandler senior research analyst Yasmin Rahini on August 7, 2025 at 11:00am EST. The company specializes in developing treatments targeting neuronal excitation-inhibition imbalance in CNS disorders.
Praxis Precision Medicines (NASDAQ:PRAX), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di terapie per disturbi del sistema nervoso centrale, ha annunciato la sua partecipazione a un prossimo incontro virtuale informale. Il CEO Marcio Souza parteciperà a una discussione con Yasmin Rahini, analista senior di ricerca presso Piper Sandler il 7 agosto 2025 alle 11:00 EST. L'azienda è specializzata nello sviluppo di trattamenti che mirano a riequilibrare l'eccitazione e l'inibizione neuronale nei disturbi del SNC.
Praxis Precision Medicines (NASDAQ:PRAX), una compañía biofarmacéutica en etapa clínica enfocada en desarrollar terapias para trastornos del sistema nervioso central, ha anunciado su participación en una próxima charla virtual informal. El CEO Marcio Souza sostendrá una conversación con Yasmin Rahini, analista senior de investigación de Piper Sandler el 7 de agosto de 2025 a las 11:00 am EST. La compañía se especializa en desarrollar tratamientos que abordan el desequilibrio entre excitación e inhibición neuronal en trastornos del SNC.
Praxis Precision Medicines (NASDAQ:PRAX)는 중추신경계 질환 치료제 개발에 주력하는 임상 단계 바이오제약 회사로, 다가오는 가상 대화 행사에 참여한다고 발표했습니다. CEO Marcio Souza는 Piper Sandler의 선임 연구 분석가 Yasmin Rahini와 2025년 8월 7일 오전 11시(동부 표준시)에 대화를 나눌 예정입니다. 이 회사는 중추신경계 질환에서 신경 흥분과 억제 불균형을 표적으로 하는 치료제 개발을 전문으로 합니다.
Praxis Precision Medicines (NASDAQ:PRAX), une société biopharmaceutique en phase clinique spécialisée dans le développement de thérapies pour les troubles du système nerveux central, a annoncé sa participation à une prochaine discussion virtuelle informelle. Le PDG Marcio Souza participera à un échange avec Yasmin Rahini, analyste principale en recherche chez Piper Sandler le 7 août 2025 à 11h00 EST. L'entreprise se spécialise dans le développement de traitements ciblant le déséquilibre entre excitation et inhibition neuronales dans les troubles du SNC.
Praxis Precision Medicines (NASDAQ:PRAX), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung von Therapien für Erkrankungen des zentralen Nervensystems spezialisiert hat, hat seine Teilnahme an einem bevorstehenden virtuellen Gespräch angekündigt. CEO Marcio Souza wird am 7. August 2025 um 11:00 Uhr EST mit Yasmin Rahini, Senior Research Analyst bei Piper Sandler, diskutieren. Das Unternehmen konzentriert sich auf die Entwicklung von Behandlungen, die das Ungleichgewicht zwischen neuronaler Erregung und Hemmung bei ZNS-Erkrankungen adressieren.
- None.
- None.
BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that CEO Marcio Souza will be participating a virtual fireside chat hosted by Piper Sandler senior research analyst Yasmin Rahini on August 7, 2025 at 11:00amEST.
The event will be webcast live and the registration link can be found here.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, Instagram, LinkedIn and Twitter/X.
Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry Life Science Advisors Daniel@lifesciadvisors.com 617-430-7576
FAQ
When is the Praxis Precision Medicines (PRAX) fireside chat with Piper Sandler?
Who will represent Praxis Precision Medicines at the Piper Sandler fireside chat?
What type of company is Praxis Precision Medicines (PRAX)?
How can investors access the Praxis Precision Medicines fireside chat?
